FDA approves a new treatment for advanced prostate cancer called Pluvicto.

The U.S. Food and Drug Administration (FDA) has approved a new treatment called Pluvicto for a specific type of advanced prostate cancer. It is for adult men with prostate cancer that has spread and has stopped responding to standard hormone treatments. This type of cancer is called metastatic castration-resistant prostate cancer. Pluvicto is a targeted radiation therapy that seeks out and delivers radiation directly to cancer cells that have a specific marker called PSMA. This approval is significant because it offers a new option for patients who have already tried other major treatments, including certain hormone therapies or chemotherapy. It represents another tool doctors can use in managing this serious disease. An important part of this approval is that patients must first have a special imaging scan to confirm their tumors have the PSMA marker. This ensures the treatment is given to those most likely to benefit. The treatment is given as an intravenous infusion every six weeks, for up to six doses. As with any new treatment, it's important to remember that this is an option for a specific group of patients. The most important step for anyone interested in this news is to have a calm and open conversation with their own doctor. A healthcare team can provide personalized information about whether this treatment might be relevant based on an individual's unique medical history and current health.